Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
. 2021 Jul 26;44(9):1549–1561. doi: 10.1111/pace.14311

Atypical pathogens associated with cardiac implantable electronic device infections

Utkarsh Kohli 1,2, Aniruddha Hazra 3, Ahmed Shahab 4, Andrew D Beaser 4, Zaid A Aziz 4, Gaurav A Upadhyay 4, Cevher Ozcan 4, Roderick Tung 4, Hemal M Nayak 4,
PMCID: PMC9290787  PMID: 34245025

Abstract

Background

Cardiovascular implantable electronic device (CIED) infections are associated with significant morbidity and mortality making the identification of the causative organism critical. The vast majority of CIED infections are caused by Staphylococcal species. CIED infections associated with atypical pathogens are rare and have not been systematically investigated. The objective of this study is to characterize the clinical course, management and outcome in patients with CIED infection secondary to atypical pathogens.

Methods

Medical records of all patients who underwent CIED system extraction at the University of Chicago Medical Center between January 2010 and November 2020 were retrospectively reviewed to identify patients with CIED infection. Demographic, clinical, infection‐related and outcome data were collected. CIED infections were divided into typical and atypical groups based on the pathogens isolated.

Results

Among 356 CIED extraction procedures, 130 (37%) were performed for CIED infection. Atypical pathogens were found in 5.4% (n = 7) and included Pantoea species (n = 2), Kocuria species (n = 1), Cutibacterium acnes (n = 1), Corynebacterium tuberculostearicum (n = 1), Corynebacterium striatum (n = 1), Stenotrophomonas maltophilia (n = 1), and Pseudozyma ahidis (n = 1). All patients with atypical CIED infections were successfully treated with total system removal and tailored antibiotic therapy. There were no infection‐related deaths.

Conclusions

CIED infections with atypical pathogens were rare and associated with good outcome if diagnosed early and treated with total system removal and tailored antimicrobial therapy. Atypical pathogens cultured from blood, tissue or hardware in patients with CIED infection should be considered pathogens and not contaminants.

Keywords: atypical microorganisms, cardiac implantable electronic device infection, lead extraction

1. INTRODUCTION

The rate of cardiac implantable electronic device (CIED) infection has increased over the last two decades and is associated with significant morbidity and mortality. 1 , 2 , 3 Early recognition and prompt system removal, including lead extraction, are recommended in most situations. Additionally, identification of the causative pathogenic microorganism is critical to guide appropriate antimicrobial therapy.

The vast majority of CIED infections are caused by Staphylococcal species (Staphylococcus aureus and coagulase‐negative staphylococci) and represent between 60% and 80% of cases. 3 , 4 Not only are staphylococcal CIED system infections highly virulent, but CIED infection secondary to methicillin‐resistant staphylococci has become an important cause of CIED infection‐related mortality. 5 Other gram‐positive cocci such as Enterococcus and Streptococcus species, gram‐negative bacilli including Escherichia coli, Enterobacter and Pseudomonas species, and fungi such as Candida albicans, have previously been reported as pathogens and account for less than 15%‐20% of cases. 6 CIED infections associated with atypical pathogens are exceedingly rare and have not been systematically studied. The objective of this study is to characterize the predisposing factors, clinical course, management and outcome in patients with CIED infection secondary to atypical pathogens.

2. METHODS

2.1. Subjects

Medical records of all patients who underwent CIED system extraction at the University of Chicago Medical Center between January 2010 and November 2020 were retrospectively reviewed to identify patients with CIED infection. Data collection and analysis was approved by The University of Chicago Institutional Review Board. Demographic data including age, gender and ethnicity as well as clinical characteristics such as, type of CIED, duration of implant, indication for CIED implantation, and underlying comorbidities were collected. Infection specific data such as presenting clinical symptoms, lab investigations, blood, pocket, generator and lead culture results, echocardiographic findings, and outcome and follow‐up details were extracted from medical records.

2.2. Definition of typical and atypical CIED infection

Typical CIED infection was defined as infection due to commonly implicated organisms 3 such as Staphylococcus aureus and Coagulase negative staphylococcus species, Streptococcus species, Enterococcus species, specific Enterobacterales (Escherichia coli, Klebsiella species, Citrobacter species, Enterobacter species, Proteus species, Serratia species), Pseudomonas species, and Candida species.

Atypical CIED infection was defined as infection due a pathogen rarely or previously not associated with CIED infections in humans. This included fastidious organisms such as the HACEK group (Haemophilus species, Aggregatibacter actinomycetemcomitans, Cardiobacterium hominis, Eeikenella corrodens, Kingella kingae) as well as pathogens rarely identified in CIED infections such as nontuberculous mycobacteria and fungi other than Candida. Of note, skin organisms such as Corynebacterium species, Microccocus species, or Cutibacterium (formerly Propionibacterium) species were also considered pathogens given their infrequent association with CIED infections in isolation.

2.3. Identification of pathogens and antimicrobial management

All patients who presented with CIED infection had a minimum of two sets of blood cultures drawn prior to initiation of antimicrobial therapy. At the time of system removal, all hardware (leads, generator) as well as a swab or tissue from the CIED pocket were sent for culture and sensitivity analysis. An atypical organism was considered pathogenic if it was cultured from blood (minimum one set of blood cultures) or cultured from hardware (explanted generator and/or leads) or if it was the only organism identified in the blood, CIED system component or CIED pocket. This definition was used to distinguish true pathogens from presumed contaminants. Advanced laboratory methods such as 16S Ribosomal DNA sequence analysis as well as matrix assisted laser desorption ionization‐time of flight mass spectrometry (MALDI‐TOF MS) were utilized for diagnosis in some patients.

The duration and choice of antimicrobial therapy was determined based on culture and sensitivity results, the presence or absence of positive blood cultures and the presence or absence of lead or valvular vegetations. Infectious disease consultation was obtained in the majority of patients.

2.4. Data analysis and statistics

Data are expressed as mean and standard deviation, or median and interquartile range as appropriate. The main focus of the report was to characterize CIED infections with atypical organisms. Given the overall rarity of atypical CIED infections, non‐parametric statistical tests including Mann‐Whitney U test and Fisher's exact test were used to evaluate differences in means and proportions, respectively, between those with typical and atypical CIED infections. p‐values < .05 were considered significant. All analyses were performed using the statistical software STATA v. 13.0 (StataCorp, College Station, Texas, USA).

3. RESULTS

3.1. Demographic data

From January 2010 to November 2020, 356 CIED extraction procedures were performed at our center. Of those, 130 (37%) were performed due to CIED infection. Atypical pathogens were identified in seven (5.4 %) patients. The clinical characteristics of these 130 patients are summarized in Table 1. The majority of the study population consisted of men; approximately 30% of the study population was African‐American. Over 50% of the CIED infections occurred in patients with implantable cardioverter‐defibrillators (ICD) or cardiac resynchronization therapy with a defibrillator (CRT‐D) devices. As expected, the study patients had many cardiovascular comorbidities. While patients with CIED infection due to typical pathogens had a higher prevalence of diabetes mellitus, there were no other major differences between the two groups.

TABLE 1.

Characteristics of patients with CIED infection

Patients with Typical Pathogens (n = 123) Patients with Atypical Pathogens (n = 7) p value

Demographics

Age (years)

65 ± 15 53 ± 25 .19
Men 85 (69%) 7 (86%) .67

Race

Caucasian

African American

Asian

63 (51%)

48 (39%)

10 (8%)

3 (43%)

2 (28%)

1 (14%)

.66

Clinical characteristic
CIED dwell time (weeks) 253 ± 228 257 ±192 .80

Ischemic cardiomyopathy

Non‐ischemic cardiomyopathy

ARVC

56 (45%)

55 (45%)

0

2 (29%)

3 (43%)

1

.32

.62

.05

Ventricular tachycardia or fibrillation 25 (20 %) 2 (29 %) .48
Previous open heart surgery 39 (32 %) 1 (14 %) .30
Complete or high grade AVB 33 (27 %) 0 .12
Sick sinus syndrome 13 (11 %) 0 .47
Congenital heart disease 1 (0.8 %) 1 (14 %) .10
Valvular heart disease 12 (10 %) 1 (14 %) .53
Peripheral vascular disease 10 (8 %) 0 .56
Atrial fibrillation 52 (42 %) 3 (43 %) .63
History of cerebrovascular accident 13 (11 %) 0 .47
Pulmonary hypertension 5 (4 %) 0 .75
Systemic hypertension 73 (59 %) 3 (43 %) .31
Diabetes mellitus 50 (41 %) 0 .03
Past or current tobacco use 57 (46 %) 4 (57 %) .60
Chronic obstructive pulmonary disease 23 (19 %) 0 .24
Obstructive sleep apnea 12 (10 %) 1 (14 %) .53
Laboratory & clinical data
WBC count at presentation (cells/μL) 8.7 ± 4.6 6.5 ± 1.9 .19
Platelet count at presentation (1000/μL) 212 ± 92 208 ± 129 .53
Glomerular filtration rate (mL/min/1.73m2) 61 ± 30 60 ± 44 .96
Left ventricular ejection fraction (%) 39 ± 16 42 ± 20 .76

Type of Device

Permanent pacemaker

Implantable cardioverter‐defibrillator

S‐ICD

CRT‐D

Other

36 (30%)

47 (38%)

1 (1%)

35 (28%)

4 (3%)

1 (14 %)

3 (43 %)

0

2 (29%)

0

.22

Infection characteristics
Positive blood cultures 67 (45%) 2 (29%) .25
Positive hardware cultures 93 (76%) 5 (71%) .68
Septic shock 22 (18 %) 0 .60
Endocarditis 36 (29%) 4 (57%) .20
Pocket infection 59 (48%) 4 (57%) .72
Duration of antibiotic therapy (weeks) 4 ± 2.2 5 ± 2.5 .30
Days between infection diagnosis and extraction 27 ± 53 26 ± 46 .23
Infection‐related deaths 22 (18%) 0 1.0

Abbreviations: AVB, atrioventricular block; ARVC, arrhythmogenic right ventricular cardiomyopathy; CIED, cardiac implantable electronic device; WBC, white blood cell; S‐ICD, subcutaneous implantable cardioverter defibrillator; CRT‐D, cardiac resynchronization therapy with a defibrillator.

Values are n (%), mean ± standard deviation.

3.2. Pathogens associated with typical CIED infections

Coagulase‐negative staphylococcus was the most commonly isolated pathogen accounting for 51% of cases (n = 66) followed by Staphylococcus aureus in 35% (n = 46). Other gram‐positive organisms isolated included Streptococcus species in 1.5% (n = 2), and Enterococcus faecalis in 8% (n = 10). Gram negative organisms such as Eischerichia coli, Enterobacter species, Pseudomonas species, Serratia species, and Klebsiella species were identified in 12% (n = 16). Candida species were isolated in 3% (n = 3). Polymicrobial infection was noted in approximately 19% (n = 25). Only one patient had culture negative CIED infection.

3.3. Pathogens associated with atypical CIED infections

Seven unique pathogens were identified in seven patients: Pantoea species (n = 2), Kocuria species (n = 1), Cutibacterium acnes (n = 1), Corynebacterium tuberculostearicum (n = 1), Corynebacterium striatum (n = 1), Stenotrophomonas maltophilia (n = 1), and Pseudozyma ahidis (n = 1). The clinical details of these and other reported patients with atypical CIED infection due to similar organisms are summarized in Table 2.

TABLE 2.

Characteristics of patients with atypical CIED infection

Authors Age (years) Gender CIED dwell time (weeks) Comorbidities Type of CIED WBC Count (109/L) Days between diagnosis and extraction Endocarditis (lead or valve) Hardware cultures Blood cultures Site culture Antibiotic sensitivity Antibiotic therapy utilized
Pantoea species
Kohli et al 52 M 359 NICM, ESRD ICD 3.4 131 3.5 cm intracardiac vegetation RV lead: Pantoea species and Staphylococcus haemolyticus Positive Both Pantoea species and Staphylococcus species were pansensitive. Vancomycin and Cefepime for 12 weeks followed by oral TMP/SM for 3 months
Kohli et al 26 M 208 NICM (EF 21%) on home milrinone therapy, BAV ICD 5.7 12 0.95 cm mobile vegetation on ICD lead

Positive

Pseudozyma aphidis

Meropenem for 48 h, Ceftriaxone for 6 weeks Micafungin for 9 days, Metronidazole for 7 days
Ajam et al 17 61 F <1 NICM, DM, HTN CRT‐D 13 A few days

Positive

Co‐infection with Stenotrophomonas maltophilia)

TMP/SM TMP/SM for 14 days
Kocuria species
Kohli et al 86 M 538 ICM, VT, AF, OSA CRT‐D 5.3 7 ICD lead

Vancomycin and cefazolin for 72 h

Dicloxacillin for 10 days

Cutibacterium acnes
Kohli et al 17 M 6

Obesity,

CPVT

ICD 9.7 7 ICD lead Pocket

Penicillin (S)

Moxifloxacin (S)

Cephalexin for 4 days

Vancomycin + Cefepime for 7 days

Oral amoxacillin for 14 days followed by long term suppressive amoxicillin

Chakour et al 33 48 M 262 SSS PPM 12 15 x 8 mm mass on the RV lead) PPM lead Positive

Penicillin (S)

Amoxicillin (S)

Erythromycin (S)

IV Amoxicillin X 1 month
Noel et al 34 74 M 104 AV block, DM, HTN PPM 15 11 6 x 3 cm mass in the right atrium) □ (PCR) Positive

Amoxicillin □ clavulanic acid

Gentamicin,

Amoxicillin□ Rifampicin for 6 weeks

Santo KRE et al 35 48 F 52 Ebstein's anomaly PPM 270 Positive Positive

Oral first generation cephalosporin

IV Ceftriaxone □ Gentamicin

Oral doxycycline

IV Vancomycin,

IV Daptomycin for 6 weeks

Gorospe L et al 36 59 M PPM Positive Positive Penicillin (S) UNK
Corynebacterium tuberculostearicum
Kohli et al 55 F 3 ARVC, VT ICD 12 RA lead and ICD generator

Cefepime for 96 h

Clindamycin for 2 weeks

Corynebacterium striatum
Kohli et al 55 M 270 ICM,LVAD, ESRD ICD 7.5 8 RA and ICD leads and LVAD driveline Vancoycin for 6 weeks, Oral Cephalexin (long term prophylaxis)
Melero‐Bascones, et al 49 73 M 312 PPM 28 Positive Positive Positive

Penicillin (R)

Vancomycin (S)

IV Vancomycin (4 weeks)

TMP/SM and Rifampin for 2 weeks

Oliva et al 46 71 F 8 PPM 11 7 Positive Positive (Sonication) Positive (CONS)

Positive

(CONS)

Penicillin (R)

Cefotaxime (R)

Gentamicin (R)

Erythromycin (R)

Levofloxacin (R)

Clindamycin (R)

Vancomycin (S)

Linezolid (S)

Daptomycin (S)

Daptomycin for 4 weeks

7 days Linezolid

Abi et al 47 51 M 28 High grade AVB PPM 5.3 Positive Positive Positive

Penicillin G (S)

Gentamicin (S) Tobramycin (S) Erythromycin (S)

Lincomycin (S)

Linezolid (S) Chloramphenicol (S) Tetracycline (S)

Rifampicin (S)

Trimethoprim/Sulfamethoxazole (S)

Ofloxacin (S) Teicoplanin (S)

Vancomycin (S)

Oxacillin (R)

Kanamycin (R)

Fosfomycin (R)

Fusidic Acid (R)

IV Ciprofloxacin □ Vancomycin for 6 weeks
Guererro et al 48 78 M 24 DM, CRF PPM 10 24 Positive Positive

Daptomycin (S)

Penicillin (R)

Cephalosporin (R)

Clindamycin (R)

Fluoroquinolones (R)

Trimethoprim/Sulfamethoxazole(R)

Doxycycline (S)

Gentamicin (S)

Linezolid (S)

Daptomycin for 3 weeks
Stenotrophomonas maltophilia
Kohli et al 79 M 100 HTN PCM 6.3 6 No PPM Generator, RA and RV lead Positive

Levofloxacin (S) Minocycline (S)

Trimethoprim/Sulfamethoxazole (S)

Vancomycin for 48 h Cefepime for 96 h ,

TMP/SM for 6 weeks

Takigawa et al 51 72 F 884 AV block, Chronic refractory middle and external otitis PCM 6.8 102 17 × 7 mm mobile vegetation on RA lead) Positive Positive

TMP/SM (S)

Minomycine (S)

Pazufloxacin (S)

Vancomycin

Ceftazidime (no response)

TMP/SM

Minomycine

Pazufloxacin

Aktuerk et al 52 93 M

CRF, IHD, AF, Dementia, HTN, Polymyalgia

Rheumatica (steroids)

PCM Positive
Reynaud et al 53 81 F 68 HTN, AF, Rhizomelic pseudo‐polyarthritis (Steroids), CRF CRT‐P 3 mobile vegetations [<10 mm] on TV) Positive Positive

Ticarcillin‐Clavulanic Acid (R)

Cephalosporins (R)

Carbapenems (R)

IV TMP/SM Moxifloxacin

Died 9 days after device extraction.

Ajam M et al 17 61 F Few days NICM, DM, HTN CRT‐D 13 A few days □ (Also, Pantoea calida) Trimethoprim‐sulfamethoxazole (S) Trimethoprim‐sulfamethoxazoleX 14 days
Rostoff et al 54 22 M 52 D‐TGA s/p Senning procedure, AV block, CHF (NYHA IV) PCM 5.5 A few days 6 × 16 mm vegetation on LV lead) Positive Positive

Ticarcillin‐Clavulanic Acid (S)

Trimethoprim‐sulfamethoxazole (R)

Ciprofloxacin (R)

Aminoglycosides (R)

β‐lactams (R)

TMP/SM amikacin

Died 9 days after surgical device and lead extraction.

Abbreviations: WBC, white blood cell; M, male; F, female; NICM, non‐ischemic cardiomyopathy; ESRD, end stage renal disease; ICD, implantable cardioverter defibrillator; RV, right ventricle; E F, ejection fraction; CONS, coagulase negative Staphylococcus; S, sensitive; R, resistant; ICM, ischemic cardiomyopathy; VT, ventricular tachycardia; VF, ventricular fibrillation; OSA, obstructive sleep apnea; CRT‐D, cardiac resynchronization therapy with a defibrillator; CPVT, catecholaminergic polymorphic ventricular tachycardia; SSS, sick sinus syndrome; PPM, permanent pacemaker; AVB, atrioventricular block; DM, diabetes mellitus; HTN, hypertension; PCR, polymerase chain reaction; ARVC, arrhythmogenic right ventricular cardiomyopathy; RV, right ventricle; RA, right atrium; LVAD, left ventricular assist device; CRF, chronic renal failure; AF, atrial fibrillation; CRT‐P, cardiac resynchronization therapy with a pacemaker; D‐TGA, D‐Transposition of great arteries; NYHA, New York Heart Association; LV, left ventricle; TV, tricuspid valve.

3.4. Panteoa species

3.4.1. Patient 1

A 52‐year‐old obese man with end stage renal disease and non‐ischemic cardiomyopathy presented with a systemic ICD infection with two sets of positive blood cultures growing undifferentiated Pantoea. Transesophageal echocardiography (TEE) revealed a 3.5 cm vegetation on his ICD lead. Prior to presentation, he had been treated with intravenous vancomycin and cefepime for 12 weeks without success. He underwent extraction of his CIED system. Hardware cultures grew undifferentiated Pantoea species and Staphylococcus haemolyticus. Both organisms were sensitive to several antibiotics. He was treated with oral trimethoprim‐sulfamethoxazole for 3 months. At 4 months follow‐up after his system extraction, the patient had no recurrent signs or symptoms of infection. He refused another ICD implant.

3.4.2. Patient 2

A 26‐year‐old man with non‐ischemic cardiomyopathy, history of ICD implant 2 years prior to presentation, and severe left ventricular dysfunction (on intravenous milrinone therapy via a peripherally inserted central catheter [PICC]) developed upper respiratory tract infection (URI) symptoms, cough, fever and rigors 3‐4 weeks prior to presentation. He denied erythema, pain, or swelling at the PICC insertion site. He was hospitalized and was noted to be in septic shock. The PICC was removed and sent for culture (PICC culture was negative). Two sets of blood cultures grew Pantoea agglomerans and he was treated with meropenem for 48 h followed by intravenous ceftriaxone. His blood cultures also grew a yeast (Pseudozyma ahidis) which was treated initially with intravenous micafungin. A TEE was performed and was notable for a bicuspid aortic valve without any significant stenosis or regurgitation and a 0.95 cm mobile vegetation on his ICD lead. He subsequently underwent extraction of his single chamber transvenous ICD system which was followed by a 6‐week course of intravenous ceftriaxone and oral voriconazole. His ICD lead culture was negative. The patient was discharged home with a wearable defibrillator. At 24 months of follow‐up, he continues to do well without any symptoms and signs of infection. He has refused another implant.

3.5. Kocuria species

An 86‐year‐old man with previous cardiac arrest and ischemic cardiomyopathy presented with erythema, skin thinning and fixation over his CIED pocket, 10 years after initial CRT‐D implant (Figure 1). Blood cultures were negative and he had no systemic symptoms. He underwent total system extraction and was treated empirically with intravenous vancomycin and cefazolin. ICD lead culture was positive for Kocuria species with no other organisms identified. A source for Kocuria infection was not found. He was switched to a 10‐day course of oral dicloxacillin and was discharged with a wearable defibrillator. At 6 months of follow‐up his pocket area had completely healed. He subsequently underwent another CRT‐D implant at an outside hospital and has done well without reinfection.

FIGURE 1.

FIGURE 1

Cardiac implantable electronic device (CIED) pocket infection secondary to Kocuria species. Erythema, thinning and fixation of the skin overlying the CIED pocket are seen predominantly over the lower lateral border of the CIED pocket. Implantable cardioverter defibrillator (ICD) lead and pocket cultures were positive for Kocuria species with no other organisms identified [Color figure can be viewed at wileyonlinelibrary.com]

3.6. Cutibacterium acnes

A 17‐year‐old boy with a malignant flecainide, nadolol, and sympathectomy refractory catecholaminergic polymorphic tachycardia phenotype caused by a large deletion in exon three of RYR2 underwent a dual chamber transvenous ICD implantation. 7 Six weeks later, he reported copious serosanguineous discharge from the ICD incision. He denied any history of fever. The patient was admitted and underwent system removal. He was discharged home on oral augmentin. Hardware and pocket‐tissue cultures grew Cutibacterium acnes. He was treated with oral amoxicillin therapy for 14 days which was followed by long term suppressive therapy with the same drug. Over 24 months of follow‐up, he has done well without recurrence of infection. Another ICD was implanted on the contralateral side.

3.7. Corynebacterium tuberculostearicum

A 55‐year‐old woman with a history of arrhythmogenic right ventricular cardiomyopathy and sustained monomorphic ventricular tachycardia underwent dual chamber ICD implantation in 2006. She underwent pulse generator change in July 2013 during which a capsulectomy was performed and an antibiotic‐eluting pouch was utilized. She began to notice worsening pain, swelling, redness, and drainage at the site without any fever 3 weeks after the procedure (Figure 2). She underwent system extraction. The ICD generator and the right atrial (RA) lead both grew Corynebacterium tuberculostearicum which was treated with oral clindamycin for 2 weeks. No other organisms were isolated. A subcutaneous defibrillator was implanted 3 days after extraction of the old system. Over 48 months of follow‐up, the patient has not had any recurrent signs or symptoms of infection.

FIGURE 2.

FIGURE 2

Cardiac implantable electronic device (CIED) pocket infection secondary to Corynebacterium tuberculostearicum. Discoloration of the skin adjacent to the surgical incision is visible. The lateral border of the incision is open 3 weeks after dual chamber ICD generator change. The implantable cardioverter defibrillator (ICD) generator and the right atrial (RA) lead both grew Corynebacterium tuberculostearicum [Color figure can be viewed at wileyonlinelibrary.com]

3.8. Corynebacterium striatum

A 55‐year‐old man with ischemic cardiomyopathy, history of dual chamber ICD implant in 2018, end stage renal disease and left ventricular assist device (LVAD) as destination therapy, presented with atypical chest pain, generalized weakness, and worsening dyspnea for a week. He endorsed tenderness and drainage around the LVAD driveline insertion site. He denied fever. He had a history of chronic LVAD driveline site infection with Corynebacterium species and a recent admission for Corynebacterium striatum bacteremia that was being treated with oral cephalexin. A TEE was performed and showed a moderate sized mobile echo density on the TV adjacent to the ICD lead. He underwent extraction of the CIED system which was followed by a 6‐week course of intravenous vancomycin. Cultures from the RA and ICD leads grew Corynebacterium striatum. Long‐term oral cephalexin was recommended. The patient died 2 months after the procedure due to intracranial complications resulting from a fall on oral anticoagulation. No recurrent signs or symptoms of infection were reported.

3.9. Stenotrophomonas maltophilia

A 79‐year‐old man with a history of hypertension and complete heart block treated with permanent pacemaker (PPM) implantation in 2017, noted increasing irritation around his pacemaker incision site. He presented with pacemaker erosion and treatment was initiated with intravenous cefepime and vancomycin. He denied any fever or symptoms suggestive of systemic infection. The transvenous PPM system was subsequently extracted and replaced with a leadless pacemaker (Micra, Medtronic, Minneapolis, Minnesota, USA). The generator, RA lead and right ventricular (RV) lead cultures grew Stenotrophomonas maltophilia which was treated with oral trimethoprim‐sulfamethoxazole for 6 weeks with resolution of symptoms. At 12 months of follow‐up, he is doing well without any recurrent signs or symptoms of infection.

4. DISCUSSION

Descriptions of CIED infections with atypical microorganisms are limited to anecdotal case reports and to the best of our knowledge, this is the first study to systematically evaluate the clinical presentation, management and outcome in patients with CIED infection secondary to atypical pathogens.

The main findings in this paper are as follows: (1) Atypical pathogens accounted for 5% of CIED infections over a 10‐year period (2) CIED infections secondary to atypical pathogens were associated with a good outcome if diagnosed early and treated with total system removal and tailored antimicrobial therapy. (3) This is the first report of CIED infection associated with Kocuria species, Pseudozyma aphidis, and isolated Corynebacterium tuberculostearicum.

The microbiology of CIED infection has changed over the last two decades. Hussein et al, reported the microbiology of CIED infection in a modern cohort of patients and found a significant rise in CIED infection secondary to methicillin‐resistant staphylococcus aureus (MRSA). MRSA infections accounted for 34% of all CIED infections and 49% of all staphylococcal infections; atypical pathogens were found in less than 0.2%, however, an increasing trend was noted during the study period. 6 CIED infection secondary to MRSA was associated with high mortality, especially in elderly patients with bacteremia. 5 A high proportion of culture negative CIED infections which were not further characterized, lack of use of advanced laboratory methods such as 16S Ribosomal DNA sequence analysis and MALDI‐TOF MS, and a different geographic location may account for the difference in prevalence of atypical CIED infections reported by Hussein et al and us. 6

Because CIED infections with atypical pathogens are rare, little is known about their presentation and outcome. Recent advancements in laboratory technology have allowed for microbial identification and diagnosis that was not previously possible. As a result, organisms historically not associated with CIED infections have now been isolated though the use of 16S ribosomal DNA sequencing as well as MALDI‐TOF mass spectrometry. This is not unique to CIED infections; atypical pathogens have been identified through these means for multiple other types of infections, expanding our understanding of these organisms as pathogenic and not simple contaminants. 8 , 9 , 10

In our study, both patients with CIED infection due to Pantoea species presented with bacteremia. Pantoea species, which are members of Enterobacterales family, are gram‐negative bacilli that are frequently found in soil and vegetation. 11 Recent studies have also reported isolation of Pantoea species from the skin of healthy humans. 12 In both immunocompetent and immunocompromised humans, Pantoea species are a rare cause of sepsis 13 which at times can be multidrug resistant. 14 One of our patients had no obvious risk factors for infection but the other had an long term PICC line which placed him at higher risk as Pantoea species have been associated with central venous catheter‐associated infections. 15 Cardiovascular infections with Pantoea species are exceedingly rare and only one patient with mitral valve endocarditis 16 and another with CIED pocket infection have been reported to date. 17 Most of the patients with Pantoea infection, including the two in our study, have done well following appropriate culture and sensitivity guided antimicrobial therapy. However, care should be exercised while using carbapenems as approximately 21% of Pantoea agglomerans isolates were noted to be carbapenem resistant in a recent series. 18

One of these patients was also co‐infected with Pseudozyma aphidis which is a rare fungal cause of infection in immunocompromised patients, particularly in those with hematological and oncological disorders. A bloodstream infection via possible gastrointestinal translocation has been suggested as a source in a handful of patients that have been reported. Most of the reported patients responded to either voriconazole, posaconazole, or amphotericin B. 19 CIED infection with Pseudozyma aphidis has not been reported to date.

One patient in our series had CIED infection due to Kocuria species which has not been previously reported. Kocuria species are gram‐positive bacteria which are rarely associated with human disease. To date, only 28 patients with Kocuria kristinae infection, the most common pathogenic species, have been reported. 20 These include patients with cholecystitis, peritonitis, abdominal abscess, bacteremia, umbilical sepsis, and urinary tract infection. 20 , 21 Cardiac involvement in Kocuria infections is very rare and only four patients with Kocuria endocarditis have been reported. 20 , 21 , 22 , 23 , 24 Kocuria species are often sensitive to vancomycin, linezolid, rifampicin, teicoplanin, cefotaxime, ampicillin/sulbactam, minocycline, and meropenem. Initial treatment of Kocuria infections should involve parenteral vancomycin in combination with another antibiotic to which the organism is susceptible. 25

The patient with Cutibacterium acnes CIED infection presented with a pocket‐only infection. Cutibacterium acens is a gram‐positive bacterium that forms part of the normal flora of the skin and oral cavity. Although primarily recognized for its role in acne, Cutibacterium acnes, can cause a range of postoperative and device‐related infections including those of cardiac shunts and prosthetics. 26 , 27 Cutibacterium acnes native valve endocarditis is rare. 28 , 29 , 30 , 31 , 32 To date, only four patients with Cutibacterium acnes mediated CIED infections have been reported. 33 , 34 , 35 , 36 In most of those cases, the infection was indolent, difficult to diagnose and occurred after a long period following device implantation.

Corynebacterium species are gram‐positive rods that colonize the skin and mucosal surfaces of humans. They are frequently isolated from clinical specimens and interpretation of their clinical relevance may be difficult. Lipophilic corynebacteria tend to be involved in infections of hospitalized patients and often show multidrug resistance. Corynebacterium tuberculostearicum has been associated with wound infection, urinary tract infection, osteomyelitis and mastitis. 37 , 38 , 39 The species is often associated with resistance to multiple antimicrobials. 40 To the best of our knowledge, there are no previous reports of isolated Corynebacterium tuberculostearicum mediated CIED infection. Corynebacterium striatum is an emerging multidrug resistant nosocomial pathogen capable of causing a variety of infections in immunocompromised and hospitalized patients. 41 , 42 Corynebacterium striatum has been associated with both native and prosthetic valve endocarditis and bone and joint infections. 43 , 44 , 45 However, CIED infections with Corynebacterium striatum are rare with only four patients reported to date. 46 , 47 , 48 , 49 Our patient had a chronic LVAD driveline site infection and bacteremia which infected the CIED system. The characteristics of all the reported patients with Corynebacterium striatum CIED system infection are summarized in Table 2.

Stenotrophomonas maltophilia, a small, aerobic, gram‐negative bacillus is a nosocomial pathogen extensively resistant to multiple antibiotics, and is also a rare cause of endocarditis. Because of its resistance to multiple antibiotics, Sternotrophomonas maltophilia endocarditis often results in frequent therapeutic failures and carries a high risk of complications and mortality. 50 CIED infections with Stenotrophomonas maltophilia are highly unusual with only five patients reported to date. 17 , 51 , 52 , 53 , 54 The characteristics of these patients are summarized in Table 2.

Our study had several limitations. This was a single center retrospective observational study from a quaternary care center. It is possible that the prevalence of bacterial colonization in the environment and on mucosal and skin surfaces differs between geographic regions. Our results therefore may not be automatically applicable to other geographic regions. Even though we utilized non‐parametric methods of statistical analysis, larger multicenter collaborative efforts can provide datasets that lead to more robust comparisons between patients with typical and atypical CIED infections. Lastly, laboratory methods based on 16S ribosomal DNA sequencing as well as MALDI‐TOF mass spectrometry were utilized for diagnosis in some but not all patients in our study. Prospective studies have shown that utilization of DNA analysis identified additional microbial species in 43% of patients with culture positive CIED infection and could therefore play a role in diagnosis of difficult to treat or culture negative CIED infections. 55

5. CONCLUSIONS

CIED infections with atypical pathogens were rare and associated with good outcome if diagnosed early and treated with total system removal and tailored antimicrobial therapy. Atypical pathogens cultured from blood, tissue or hardware in patients with CIED infection should be considered pathogens and not contaminants. Large multicenter studies are required to further characterize the determinants and outcomes in patients with atypical CIED infections.

CONFLICT OF INTEREST

None.

AUTHOR CONTRIBUTIONS

Drs. Kohli and Shahab were involved in data collection. Dr. Kohli carried out the analysis and wrote the initial draft. Drs. Shahab, Hazra, Aziz, Beaser, Upadhyay, Tung and Nayak took part in planning, writing, revising, and reviewing the final draft of this manuscript. All co‐authors contributed fully in terms of the design of the study, the evaluation of data, the actual manuscript preparation, and the revision and approval of the final submitted manuscript. The corresponding author confirms that all authors have seen and approved the final text.

ACKNOWLEDGMENTS

This research did not receive any specific grant from funding agencies in the public, commercial, or not‐for‐profit sectors.

Kohli U, Hazra A, Shahab A, et al. Atypical pathogens associated with cardiac implantable electronic device infections. Pacing Clin Electrophysiol. 2021;44:1549–1561. 10.1111/pace.14311

DATA AVAILABILITY STATEMENT

Some of the data underlying this article are available in the article. The authors will be happy to share the complete dataset upon request.

REFERENCES

  • 1. Nielsen JC, Gerdes JC, Varma N. Infected cardiac‐implantable electronic devices: prevention, diagnosis, and treatment. Eur Heart J. 2015;36:2484‐2490. [DOI] [PubMed] [Google Scholar]
  • 2. Korantzopoulos P, Sideris S, Dilaveris P, Gatzoulis K, Goudevenos JA. Infection control in implantation of cardiac implantable electronic devices: current evidence, controversial points, and unresolved issues. Europace. 2016;18:473‐478. [DOI] [PubMed] [Google Scholar]
  • 3. Padfield GJ, Steinberg C, Bennett MT, et al. Preventing cardiac implantable electronic device infections. Heart Rhythm. 2015;12:2344‐2356. [DOI] [PubMed] [Google Scholar]
  • 4. Kusumoto FM, Schoenfeld MH, Wilkoff BL, et al. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. Heart Rhythm. 2017;14:e503‐e551. [DOI] [PubMed] [Google Scholar]
  • 5. Greenspon AJ, Rhim ES, Mark G, Desimone J, Ho RT. Lead‐associated endocarditis: the important role of methicillin‐resistant staphylococcus aureus. Pacing Clin Electrophysiol. 2008;31:548‐553. [DOI] [PubMed] [Google Scholar]
  • 6. Hussein AA, Baghdy Y, Wazni OM, et al. Microbiology of cardiac implantable electronic device infections. JACC Clin Electrophysiol. 2016;2:498‐505. [DOI] [PubMed] [Google Scholar]
  • 7. Kohli U, Aziz Z, Beaser AD, Nayak HM. A large deletion in RYR2 exon 3 is associated with nadolol and flecainide refractory catecholaminergic polymorphic ventricular tachycardia. Pacing Clin Electrophysiol. 2019;42:1146‐1154. [DOI] [PubMed] [Google Scholar]
  • 8. Schröttner P, Gunzer F, Schüppel J, Rudolph WW. Identification of rare bacterial pathogens by 16S rRNA gene sequencing and MALDI‐TOF MS. J Vis Exp. 2016;113:53176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Singhal N, Kumar M, Kanaujia PK, Virdi JS. MALDI‐TOF mass spectrometry: an emerging technology for microbial identification and diagnosis. Front Microbiol. 2015;6:791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. DeMarco ML, Ford BA. Beyond identification: emerging and future uses for MALDI‐TOF mass spectrometry in the clinical microbiology laboratory. Clin Lab Med. 2013;33:611‐628. [DOI] [PubMed] [Google Scholar]
  • 11. Walterson AM, Pantoea SJ. Insights into a highly versatile and diverse genus within the enterobacteriaceae. FEMS Microbiol Rev. 2015;39:968‐984. [DOI] [PubMed] [Google Scholar]
  • 12. Shami A, Al‐Mijalli S, Pongchaikul P, Al‐Barrag A, AbduRahim S. The prevalence of the culturable human skin aerobic bacteria in Riyadh, Saudi Arabia. BMC Microbiol. 2019;19:189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Dutkiewicz J, Mackiewicz B, Kinga Lemieszek M, Golec M, Milanowski J. Pantoea agglomerans: a mysterious bacterium of evil and good. Part III. Deleterious effects: infections of humans, animals and plants. Ann Agric Environ Med. 2016;23:197‐205. [DOI] [PubMed] [Google Scholar]
  • 14. Agyepong N, Govinden U, Owusu‐Ofori A, Essack SY. Multidrug‐resistant gram‐negative bacterial infections in a teaching hospital in Ghana. Antimicrob Resist Infect Control. 2018;7:37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Wong KW. Pantoea agglomerans as a rare cause of catheter‐related infection in hemodialysis patients. J Vasc Access. 2013;14:306. [DOI] [PubMed] [Google Scholar]
  • 16. Hrabińska‐Zachwieja J, Krukowski J, Tubek S, Zeljaś A. Bacterial endocarditis caused by enterobacter agglomerans in a patient with mitral valve leaflet prolapse. Wiad Lek. 1989;42:453‐455. (in Polish). [PubMed] [Google Scholar]
  • 17. Ajam M, Shokr M, Ajam F, Lieberman R. Rare case of implantable cardioverter defibrillator infection caused by stenotrophomonas maltophilia and pantoea calida. BMJ Case Rep. 2019;12:e230506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Büyükcam A, Tuncer Ö, Gür D, et al. Clinical and microbiological characteristics of Pantoea agglomerans infection in children. J Infect Public Health. 2018;11:304‐309. [DOI] [PubMed] [Google Scholar]
  • 19. Telles JP, Ribeiro VST, Kraft L, Tuon FF. Pseudozyma spp. human infections: a systematic review. Med Mycol. 2020;59(1):1‐6. [DOI] [PubMed] [Google Scholar]
  • 20. Napolitani M, Troiano G, Bedogni C, Messina G, Nante N. Kocuria kristinae: an emerging pathogen in medical practice. J Med Microbiol. 2019;68:1596‐1603. [DOI] [PubMed] [Google Scholar]
  • 21. Garcia DC, Nascimento R, Soto V, Mendoza CE. A rare native mitral valve endocarditis successfully treated after surgical correction. BMJ Case Rep. 2014;2014:bcr2013202610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Citro R, Prota C, Greco L, et al. Kocuria kristinae endocarditis related to diabetic foot infection. J Med Microbiol. 2013;62:932‐934. [DOI] [PubMed] [Google Scholar]
  • 23. Lai CC, Wang JY, Lin SH, et al. Catheter‐related bacteraemia and infective endocarditis caused by kocuria species. Clin Microbiol Infect. 2011;17:190‐192. [DOI] [PubMed] [Google Scholar]
  • 24. Srinivasa KH, Agrawal N, Agarwal A, Manjunath CN. Dancing vegetations: kocuria rosea endocarditis. BMJ Case Rep. 2013;2013:pii:bcr2013010339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Živković Zarić RS, Pejčić AV, Janković SM, et al. Antimicrobial treatment of kocuria kristinae invasive infections: systematic review. J Chemother. 2019;31:109‐119. [DOI] [PubMed] [Google Scholar]
  • 26. Perry A, Lambert P. Propionibacterium acnes: infection beyond the skin. Expert Rev Anti Infect Ther. 2011;9:1149‐1156. [DOI] [PubMed] [Google Scholar]
  • 27. Banzon JM, Rehm SJ, Gordon SM, Hussain ST, Pettersson GB, Shrestha NK. Propionibacterium acnes endocarditis: a case series. Clin Microbiol Infect. 2017;23:396‐399. [DOI] [PubMed] [Google Scholar]
  • 28. Hussain A, Nasir N, Jamil B. An unusual pathogen causing native valve endocarditis. J Ayub Med Coll Abbottabad. 2016;28:824‐825. [PubMed] [Google Scholar]
  • 29. Yamamoto R, Miyagawa S, Hagiya H, et al. Silent native‐valve endocarditis caused by propionibacterium acnes. Intern Med. 2018;57:2417‐2420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Mohsen AH, Price A, Ridgway E, West JN, Green S, McKendrick MW. Propionibacterium acnes endocarditis in a native valve complicated by intraventricular abscess: a case report and review. Scand J Infect Dis. 2001;33:379‐380. [DOI] [PubMed] [Google Scholar]
  • 31. Caballero Güeto J, Arana R, Calle G, del Rio EG, Sancho M, Pinero C. Endocarditis aguda sobre válvula aórtica nativa por propionibacterium acnes acute endocarditis of the native aortic valve caused by propionibacterium acnes. Rev Esp Cardiol. 1997;50:906‐908. Spanish. [DOI] [PubMed] [Google Scholar]
  • 32. Moreira AL, Haslett PA, Symmans WF. Propionibacterium acnes as the cause of endocarditis in a liver transplant recipient. Clin Infect Dis. 2000;30:224‐226. [DOI] [PubMed] [Google Scholar]
  • 33. Chakour M, Revel F, Godreuil C, Plotton C, Aubry A, Koeck JL. Endocardite infectieuse à propionibacterium acnes sur prothèse mécanique mitrale et sur sonde de stimulateur cardiaque infectious endocarditis due to propionibacterium acnes on a mechanical heart valve and cardiac stimulator electrode. Presse Med. 2002;31:1414. French [PubMed] [Google Scholar]
  • 34. Noel W, Hammoudi N, Wegorowska E, D'Alessandro C, Steichen O. Pacemaker endocarditis caused by propionibacterium acnes: a case report. Heart Lung. 2012;41:e21‐e23. [DOI] [PubMed] [Google Scholar]
  • 35. Santo KR, Franceschi V, Campos AC, et al. Pacemaker endocarditis caused by propionibacterium acnes in an adult patient with Ebstein's anomaly: a report of a rare case. Heart Lung Circ. 2014;23:e222‐e225. [DOI] [PubMed] [Google Scholar]
  • 36. Gorospe L, Miguelena‐Hycka J, Martín‐García M, Ajuria‐Illarramendi O, Almeida‐Aróstegui NA. Propionibacterium acnes pacemaker endocarditis in a patient with a redundant loop of the ventricular lead: PET/CT findings. Clin Nucl Med. 2020;45:e55‐e56. [DOI] [PubMed] [Google Scholar]
  • 37. Paviour S, Musaad S, Roberts S, et al. Corynebacterium species isolated from patients with mastitis. Clin Infect Dis. 2002;35:1434‐1440. [DOI] [PubMed] [Google Scholar]
  • 38. Kalt F, Schulthess B, Sidler F, et al. Corynebacterium species rarely cause orthopedic infections. J Clin Microbiol. 2018;56:e01200‐e01218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Hinic V, Lang C, Weisser M, Straub C, Frei R, Goldenberger D. Corynebacterium tuberculostearicum: a potentially misidentified and multiresistant corynebacterium species isolated from clinical specimens. J Clin Microbiol. 2012;50:2561‐2567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Szemraj M, Kwaszewska A, Pawlak R, Szewczyk EM. Macrolide, lincosamide, and streptogramin B resistance in lipophilic corynebacteria inhabiting healthy human skin. Microb Drug Resist. 2014;20:404‐409. [DOI] [PubMed] [Google Scholar]
  • 41. Datta P, Gupta V, Gupta M, Pal K, Chander J. Corynebacterium striatum: an emerging nosocomial pathogen. Infect Disord Drug Targets. 2020;21(2):301‐303. [DOI] [PubMed] [Google Scholar]
  • 42. Nudel K, Zhao X, Basu S, et al. Genomics of corynebacterium striatum, an emerging multidrug‐resistant pathogen of immunocompromised patients. Clin Microbiol Infect. 2018;24:1016.e7‐1016.e13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Rasmussen M, Mohlin AW, Nilson B. From contamination to infective endocarditis‐a population‐based retrospective study of corynebacterium isolated from blood cultures. Eur J Clin Microbiol Infect Dis. 2020;39:113‐119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Lee JY, Lee SH, Kim WH. Three‐valve endocarditis caused by corynebacterium striatum. Korean Circ J. 2018;48:861‐862. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Noussair L, Salomon E, El Sayed F, et al. Monomicrobial bone and joint infection due to corynebacterium striatum: literature review and amoxicillin‐rifampin combination as treatment perspective. Eur J Clin Microbiol Infect Dis. 2019;38:1269‐1278. [DOI] [PubMed] [Google Scholar]
  • 46. Oliva A, Belvisi V, Iannetta M, et al. Pacemaker lead endocarditis due to multidrug‐resistant corynebacterium striatum detected with sonication of the device. J Clin Microbiol. 2010;48:4669‐4671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Abi R, Ez‐Zahraouii K, Ghazouani M, et al. Endocardite à corynebacterium striatum chez un porteur de stimulateur cardiaque [A corynebacterium striatum endocarditis on a carrier of pacemaker]. Ann Biol Clin (Paris). 2012;70:329‐331. French. [DOI] [PubMed] [Google Scholar]
  • 48. Fernández Guerrero ML, Robles I, Nogales Mdel C, Nuevo D. Corynebacterium striatum: an emerging nosocomial drug‐resistant endocardial pathogen. J Heart Valve Dis. 2013;22:428‐430. [PubMed] [Google Scholar]
  • 49. Melero‐Bascones M, Muñoz P, Rodríguez‐Créixems M, Bouza E. Corynebacterium striatum: an undescribed agent of pacemaker‐related endocarditis. Clin Infect Dis. 1996;22:576‐577. [DOI] [PubMed] [Google Scholar]
  • 50. Khan IA, Mehta NJ. Stenotrophomonas maltophilia endocarditis: a systematic review. Angiology. 2002;53:49‐55. [DOI] [PubMed] [Google Scholar]
  • 51. Takigawa M, Noda T, Kurita T, et al. Extremely late pacemaker‐infective endocarditis due to stenotrophomonas maltophilia. Cardiology. 2008;110:226‐229. [DOI] [PubMed] [Google Scholar]
  • 52. Aktuerk D, Lutz M, Luckraz H. Images in emergency medicine. An unusual swelling at the pacemaker pocket site. Pacemaker pocket infection caused by stenotrophomonas maltophilia. Ann Emerg Med. 2014;63:391‐403. [DOI] [PubMed] [Google Scholar]
  • 53. Reynaud Q, Weber E, Gagneux‐Brunon A, et al. Late stenotrophomonas maltophilia pacemaker infective endocarditis. Med Mal Infect. 2015;45:95‐97. [DOI] [PubMed] [Google Scholar]
  • 54. Rostoff P, Paradowski A, Gackowski A, et al. Stenotrophomonas maltophilia pacemaker endocarditis in a patient with d‐transposition of the great arteries after atrial switch procedure. Int J Cardiol. 2010;145:e92‐5. [DOI] [PubMed] [Google Scholar]
  • 55. Pichlmaier M, Knigina L, Kuehn C, et al. The role of cohabitant unusual bacterial species in infection of cardiovascular implantable electronic devices (CIED). Technol Health Care. 2013;21:87‐96. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Some of the data underlying this article are available in the article. The authors will be happy to share the complete dataset upon request.


Articles from Pacing and Clinical Electrophysiology are provided here courtesy of Wiley

RESOURCES